SB 1548
Plain-language analysis
Generated analysis, not an official summary or legal advice. Confirm with linked Oregon documents.
SB 1548 mandates the Oregon Liquor and Cannabis Commission (OLCC) to adopt rules requiring child-resistant packaging, individually wrapped cannabinoid edibles (excluding potable liquids), and specific potency limits for marijuana items. The measure establishes distinct concentration standards for medical and adult-use consumers, caps individual edible potency at 10 milligrams of adult use cannabinoid and package potency at 100 milligrams, and applies to sales on or after January 1, 2027. Official analysis indicates minimal fiscal impact.
Basis: Bill text · Source: Senate Amendments to Introduced
Official sources do not state why this measure was proposed.
Sponsor testimony, staff summaries, committee materials, or statutory findings may explain it.
Inferred from cited text; not a stated purpose.
The legislature likely aims to reduce accidental pediatric exposure and curb marketing tactics that appeal to youth by mandating individual wrapping and prohibiting imagery associated with minors, while addressing dosing safety through potency caps.
Basis: Inferred · Source: Senate Amendments to Introduced
Must adopt rules for packaging and potency in consultation with the Oregon Health Authority and State Department of Agriculture; constrained by statutory caps on individual and package potency; required to consider cost to consumers and environmental impact; prohibited from adopting rules more restrictive than reasonably necessary.
Basis: Bill text · Source: Senate Amendments to Introduced
Must transfer or sell products meeting new packaging and potency standards; must accommodate different concentration levels for medical consumers versus non-medical consumers if OLCC rules allow.
Basis: Bill text · Source: Senate Amendments to Introduced
Must use child-resistant packaging; must individually wrap each edible (except potable liquids); must avoid imagery or characters primarily associated with minors; must ensure products meet potency limits.
Basis: Bill text · Source: Senate Amendments to Introduced
May access higher potency levels than non-medical consumers if OLCC rules permit; subject to the statutory cap of up to 10 milligrams per individual edible and 100 milligrams per package.
Basis: Bill text · Source: Senate Amendments to Introduced
Subject to potency caps and packaging requirements; access to product formulations limited by the 10mg individual edible cap.
Basis: Bill text · Source: Senate Amendments to Introduced
Packaging costs may increase due to the mandate for individually wrapped edibles, though OLCC must consider the cost impact on consumers when adopting rules.
Basis: Bill text · Source: Senate Amendments to Introduced
Product formulation is restricted; individual edibles cannot exceed 10 milligrams of adult use cannabinoid, limiting single-serving potency regardless of consumer tolerance.
Basis: Bill text · Source: Senate Amendments to Introduced
Potable liquid edibles are exempt from individual wrapping, creating a regulatory distinction that may influence product development toward liquid formats.
Basis: Bill text · Source: Senate Amendments to Introduced
Revenue impact is minimal, suggesting packaging and potency changes are unlikely to significantly alter tax collections or market sales volumes.
Basis: Stakeholder claim · Sources: Revenue Impact Statement A; IS_Impact SB 1548 A2
Medical Consumer with High Tolerance
A medical patient requires high-dose relief for chronic pain. The ability to purchase a package containing 100 milligrams of cannabinoids (e.g., ten 10mg edibles) allows effective symptom management without consuming excessive volume, while strict child-resistant packaging prevents accidental ingestion by household children.
Basis: Inferred · Source: Senate Amendments to Introduced
Small Medical Cultivator
A small-scale medical cultivator relies on bulk-packaged edibles for cost efficiency. The mandate to individually wrap every edible imposes prohibitive costs that force the business to exit the market, reducing medical patient access and choice, despite OLCC's obligation to consider consumer costs.
Basis: Inferred · Source: Senate Amendments to Introduced
The text permits the liquid exemption and potency caps but does not define 'potable liquid' with sufficient precision to prevent misclassification of viscous or semi-solid edibles.
Sources · Senate Amendments to Introduced
The measure prioritizes youth protection and standardized dosing safety over packaging flexibility and potential cost savings by mandating individually wrapped edibles and capping individual potency at 10 milligrams.
Reduces risk of pediatric accidental ingestion through mandatory child-resistant packaging and individual wrapping.
Basis: Bill text · Source: Senate Amendments to Introduced
Limits impulse overconsumption via single-serving potency caps.
Basis: Bill text · Source: Senate Amendments to Introduced
Preserves medical access to differentiated potency levels distinct from adult-use standards.
Basis: Bill text · Source: Senate Amendments to Introduced
Increases packaging costs and waste for all edible products due to individual wrapping mandate.
Basis: Bill text · Source: Senate Amendments to Introduced
Restricts product innovation and consumer choice by capping individual serving size at 10 milligrams regardless of medical necessity or tolerance.
Basis: Bill text · Source: Senate Amendments to Introduced
No substantive changes between the Senate Amendments to Introduced and the A-Engrossed versions. The Senate Amendments replaced the printed bill text with provisions that are substantively identical to the A-Engrossed version regarding packaging mandates, potency caps, medical distinctions, and effective dates.
No substantive change identified.
Tradeoff: The measure prioritizes youth protection and standardized dosing safety over packaging flexibility and potential cost savings by mandating individually wrapped edibles and capping individual potency at 10 milligrams.
high confidence. The bill text is explicit regarding packaging mandates, potency caps, medical distinctions, and effective dates. Official fiscal analysis confirms minimal impact. The comparison shows no substantive changes between versions.
Possible effects if adopted; not current bill text.
The amendment delays the effective date of SB 1548’s edible potency and packaging requirements from January 1, 2027 to January 1, 2028, giving licensed manufacturers and retailers an additional year to reformulate products, redesign packaging, and clear non-compliant inventory before enforcement begins.
Basis: Stakeholder claim · Sources: Amendment -A2 — proposed amendment; Senate Amendments to Introduced
Official sources do not state why this measure was proposed.
Sponsor testimony, staff summaries, committee materials, or statutory findings may explain it.
Inferred from cited text; not a stated purpose.
Shifting the compliance deadline by twelve months likely aims to reduce immediate industry transition costs, prevent inventory waste from product recalls or destruction, and provide regulators additional time to finalize rulemaking before enforcement obligations begin.
Basis: Inferred · Sources: Amendment -A2 — proposed amendment; Staff Measure Summary A
Gain one additional year to reformulate edibles, source individually wrapped packaging, and manage compliance costs without facing immediate inventory write-offs.
Basis: Inferred · Sources: Staff Measure Summary A; IS_Impact SB 1548 A2
Can continue stocking current edible inventory through December 31, 2027 without facing immediate removal mandates or compliance penalties.
Basis: Inferred · Source: Senate Amendments to Introduced
Experience delayed access to uniformly dosed (10mg max per edible) and child-resistant packaged products; may face temporary price volatility or supply adjustments during the extended transition period.
Basis: Inferred · Source: Staff Measure Summary A
Receive an extended rulemaking and training timeline before enforcement obligations begin on January 1, 2028.
Basis: Inferred · Source: Senate Amendments to Introduced
Compliance deadlines shift by twelve months, reducing immediate operational disruption for licensed producers and allowing phased inventory turnover.
Basis: Inferred · Source: Amendment -A2 — proposed amendment
Non-compliant edible inventory can be legally sold through 2027, minimizing financial loss from product destruction or forced recalls.
Basis: Inferred · Source: Senate Amendments to Introduced
OLCC gains additional time to finalize packaging standards, potency testing protocols, and retailer guidance before the January 1, 2028 operative date.
Basis: Inferred · Source: Senate Amendments to Introduced
State and local tax revenue collection remains unaffected in the short term, as all official fiscal analyses classify the measure as having minimal revenue impact.
Basis: Stakeholder claim · Sources: IS_Impact SB 1548 1; Fiscal Impact Statement A
Manufacturers and public health stakeholders
Manufacturers successfully transition to compliant packaging without massive waste; consumers receive consistently dosed, child-resistant edibles that significantly reduce accidental pediatric exposures and overconsumption incidents.
Basis: Inferred · Source: Staff Measure Summary A
Consumers and regulatory agencies
Prolonged market availability of unindividually-wrapped or high-potency edibles increases the risk of accidental ingestion by minors or adverse health events during the extended compliance window; OLCC enforcement faces resource strain if rules are finalized late in 2027 and retailers struggle with last-minute compliance.
Basis: Inferred · Source: Senate Amendments to Introduced
inference
Sources · Senate Amendments to Introduced
Extending the compliance window reduces immediate industry costs and inventory waste but prolongs the availability of unregulated edible formats that pose public health risks.
Lower transition costs for processors and reduced product waste from delayed enforcement.
Basis: Inferred · Source: Amendment -A2 — proposed amendment
Extended rulemaking timeline for regulators to finalize standards before implementation.
Basis: Inferred · Source: Senate Amendments to Introduced
Continued market availability of potentially hazardous packaging and potency formats delays public health protections.
Basis: Inferred · Source: Staff Measure Summary A
Potential consumer confusion during the extended transition period and delayed access to uniformly dosed products.
Basis: Inferred · Source: Staff Measure Summary A
high confidence. The amendment text is explicit, fiscal impacts are uniformly classified as minimal by official state offices, and the operative date shift is clearly documented in both the amendment and current bill text.
The amendment delays the implementation of new cannabis edible packaging and potency rules by one year, shifting the statutory compliance deadline from January 1, 2027, to January 1, 2028. This extension provides manufacturers and retailers additional time to adjust production workflows, secure compliant packaging materials, and navigate OLCC rulemaking without facing immediate regulatory penalties or inventory write-offs.
Basis: Inferred · Sources: Amendment -A2 — proposed amendment; Senate Amendments to Introduced
Official sources do not state why this measure was proposed.
Sponsor testimony, staff summaries, committee materials, or statutory findings may explain it.
Inferred from cited text; not a stated purpose.
The amendment likely aims to provide additional compliance time for manufacturers and retailers to adapt to new packaging mandates, particularly given the logistical and cost implications of individually wrapping edibles. This inference is drawn from the measure's requirement for individually wrapped edibles and the OLCC's rulemaking timeline, which typically requires lead time before statutory deadlines take effect.
Basis: Inferred · Sources: Amendment -A2 — proposed amendment; Staff Measure Summary A
Gain an extra year to redesign packaging, source materials, and adjust production workflows for individually wrapped edibles without immediate compliance pressure.
Basis: Inferred · Source: Staff Measure Summary A
Delay the need to pull non-compliant inventory from shelves and gain more time to coordinate with suppliers on compliant stock and manage shelf space transitions.
Basis: Inferred · Source: Staff Measure Summary A
Receive an extended timeline to finalize rules under ORS 475C.612 and 475C.620 before enforcement begins, reducing rushed rulemaking pressure.
Basis: Inferred · Source: Senate Amendments to Introduced
Continue accessing current packaging formats for one additional year, with potential minor price stabilization as industry absorbs compliance costs over a longer period rather than passing immediate costs to buyers.
Basis: Inferred · Source: IS_Impact SB 1548 A2
Manufacturers can defer capital expenditures on new wrapping equipment or contract packaging services until 2028. Retailers face extended grace periods for inventory turnover. OLCC may need to adjust rulemaking milestones to align with the new operative date.
Basis: Inferred · Sources: Staff Measure Summary A; Senate Amendments to Introduced
Defers industry compliance costs (packaging redesign, testing, labeling) by one fiscal year, potentially reducing short-term price increases passed to consumers. No change to consumer eligibility or medical versus adult-use distinctions.
Basis: Inferred · Source: IS_Impact SB 1548 A2
Reduces immediate regulatory friction but extends the period during which products may not meet the intended child-safety or potency-standardization goals. Compliance auditing will shift focus to 2028 readiness rather than 2027 deadlines.
Basis: Inferred · Source: Staff Measure Summary A
Cannabis manufacturers facing supply chain constraints
A manufacturer avoids production halts and potential fines by using the extra year to secure alternative vendors for child-resistant, individually wrapped packaging and scale compliant inventory smoothly, maintaining market stability and preventing retail shortages.
Basis: Inferred · Source: Staff Measure Summary A
Minors and public health advocates
A minor gains prolonged access to edibles in non-individually wrapped, potentially less secure packaging that could be mistaken for conventional candy or snacks, increasing accidental ingestion risk during the extended compliance window before enhanced safeguards take effect.
Basis: Inferred · Source: Staff Measure Summary A
The amendment only postpones the operative date; it does not exempt products from child-safety standards or potency limits indefinitely. Misapplication of the delay could violate existing ORS 475C packaging and labeling requirements.
Sources · Amendment -A2 — proposed amendment; Senate Amendments to Introduced
Extending the compliance deadline reduces short-term industry costs and operational disruption but prolongs the period before enhanced child-safety and potency-standardization protections take effect. Upsides include smoother industry adaptation, deferred capital expenditures, and reduced immediate market volatility; downsides include delayed public health safeguards, extended regulatory uncertainty for market participants, and prolonged exposure to current packaging limitations.
Smoother industry adaptation to individually wrapped edible mandates without rushed production scaling.
Basis: Inferred · Source: Staff Measure Summary A
Deferred capital expenditures on packaging equipment and contract services, preserving short-term cash flow for licensed producers.
Basis: Inferred · Source: IS_Impact SB 1548 A2
Reduced immediate market volatility as retailers manage inventory transitions gradually rather than facing a hard cutoff.
Basis: Inferred · Source: Staff Measure Summary A
Delayed public health safeguards that aim to prevent minor access and standardize dosing across the market.
Basis: Inferred · Source: Staff Measure Summary A
Extended regulatory uncertainty for market participants navigating OLCC rulemaking timelines alongside the postponed operative date.
Basis: Inferred · Source: Senate Amendments to Introduced
Prolonged exposure to current packaging limitations that may not fully align with child-safety or potency-standardization goals.
Basis: Inferred · Source: Staff Measure Summary A
high confidence. The amendment text is explicit about changing the operative date. Official fiscal and revenue analyses confirm minimal impact, and staff summaries detail the underlying packaging and potency requirements that are being delayed.
If adopted, the amendment would mandate individually wrapped cannabinoid edibles, cap adult-use edibles at 10 milligrams per piece and 100 milligrams per package, require the Oregon Liquor and Cannabis Commission to establish separate potency limits for medical cardholders versus non-cardholders, and prohibit packaging or marketing likely to attract minors. Material consequences include mandatory product reformulation or repackaging by licensed retailers and processors, updated compliance protocols, and stricter enforcement of minor-access prevention standards beginning January 1, 2027.
Basis: Inferred · Source: Amendment -1 — proposed amendment
Official sources do not state why this measure was proposed.
Sponsor testimony, staff summaries, committee materials, or statutory findings may explain it.
Inferred from cited text; not a stated purpose.
The statutory focus on individually wrapped edibles and explicit per-serving potency caps suggests an intent to standardize dosing safety and reduce accidental pediatric ingestion or overconsumption, aligning with public health models for regulated consumables.
Basis: Inferred · Source: Amendment -1 — proposed amendment
Must reformulate products, source compliant packaging, update labeling, and ensure marketing aligns with new minor-access prohibitions.
Basis: Inferred · Source: Amendment -1 — proposed amendment
Will be subject to distinct potency guidelines; OLCC must consider symptom mitigation when setting medical limits, potentially preserving higher concentrations for therapeutic use.
Basis: Inferred · Source: Amendment -1 — proposed amendment
Reduced risk of accidental ingestion or marketing-driven access due to mandatory individual wrapping and stricter packaging/marketing standards.
Basis: Inferred · Source: Amendment -1 — proposed amendment
Minimal direct fiscal impact, though consumers may face adjusted retail pricing to offset licensee compliance costs.
Basis: Inferred · Source: Staff Measure Summary A
Retailers must ensure all edibles are individually wrapped and comply with strict potency caps, shifting formulation and supply chain operations. Marketing materials cannot use imagery likely to attract minors, constraining design options. OLCC gains explicit authority to define objective criteria for minor-access packaging, moving enforcement toward visual/marketing compliance alongside chemical testing. Compliance costs will be borne by licensees, though legislative staff assess the overall revenue impact as minimal.
Basis: Inferred · Sources: Amendment -1 — proposed amendment; Fiscal Impact Statement A; Revenue Impact Statement A
Minors and emergency responders
A child accidentally accesses a package of edibles but cannot reach individual pieces due to mandatory wrapping and child-resistant standards, preventing a severe overdose while allowing emergency responders to quickly identify the exact product consumed for targeted treatment.
Basis: Inferred · Source: Amendment -1 — proposed amendment
Small medical dispensaries and high-tolerance patients
A small medical dispensary faces insurmountable costs to reformulate high-potency products or must discontinue specialized medical formulations entirely if OLCC sets uniform caps that do not adequately account for therapeutic tolerance, reducing available options for patients with severe conditions.
Basis: Inferred · Source: Amendment -1 — proposed amendment
The text legally permits OLCC to set differentiated standards for medical versus adult-use markets and allows flexibility in packaging design. However, weak enforcement of the objective criteria for minor-access packaging could lead to duty creep where OLCC bans visually distinct or culturally specific edible designs under broad likely-to-attract-minors language, effectively restricting lawful commercial expression without clear statutory boundaries.
Sources · Amendment -1 — proposed amendment
The measure prioritizes standardized dosing and minor-access prevention over product variety and formulation flexibility for both medical and adult-use markets. Upsides include clearer safety standards and reduced pediatric risk; downsides include compliance costs, potential reduction in specialized medical products, and constrained marketing/design options for licensed retailers.
Clearer safety standards and reduced pediatric risk
Basis: Inferred · Source: Amendment -1 — proposed amendment
Compliance costs, potential reduction in specialized medical products, and constrained marketing/design options for licensed retailers
Basis: Inferred · Source: Amendment -1 — proposed amendment
high confidence. Analysis is grounded in the explicit statutory text of the proposed amendment and official legislative revenue/fiscal statements. Inferences are clearly labeled and bounded to the provided text.
The amendment would mandate that all retail cannabinoid edibles be individually wrapped, cap potency at 10 milligrams per edible and 100 milligrams per package, require child-resistant packaging with explicit anti-child-appeal criteria, and establish separate potency limits for medical versus adult-use consumers. Material consequences include standardized dosing formats, mandatory packaging redesigns for manufacturers, OLCC rulemaking obligations, and a structural reduction in accidental pediatric exposure risks.
Basis: Stakeholder claim · Source: Amendment -1 — proposed amendment
Official sources do not state why this measure was proposed.
Sponsor testimony, staff summaries, committee materials, or statutory findings may explain it.
Inferred from cited text; not a stated purpose.
Lawmakers appear to aim at standardizing dosing to prevent accidental overconsumption while explicitly targeting packaging designs that appeal to children.
Basis: Inferred · Source: Amendment -1 — proposed amendment
Must reformulate packaging to individually wrap each edible, adjust potency limits per serving and package, and ensure marketing or packaging avoids imagery or characters primarily associated with minors.
Basis: Stakeholder claim · Source: Amendment -1 — proposed amendment
Must comply with identical packaging standards but may receive distinct potency concentration rules tailored to symptom mitigation rather than fixed retail caps.
Basis: Stakeholder claim · Source: Amendment -1 — proposed amendment
Will encounter standardized 10-milligram per edible servings and a 100-milligram maximum per package, altering dosing practices and limiting high-potency single-unit options.
Basis: Stakeholder claim · Source: Amendment -1 — proposed amendment
Face reduced risk of accidental ingestion due to mandated child-resistant packaging and explicit prohibitions on minor-associated marketing or design elements.
Basis: Stakeholder claim · Source: Amendment -1 — proposed amendment
Consumers will need to adjust to fixed 10-milligram servings; medical patients may access higher concentrations if permitted by separate medical rules, but retail is capped at 100 milligrams per package.
Basis: Stakeholder claim · Source: Amendment -1 — proposed amendment
Manufacturers face packaging redesign costs and compliance audits. OLCC bears rulemaking and enforcement costs, though fiscal impact is minimal.
Basis: Stakeholder claim · Sources: Amendment -1 — proposed amendment; Fiscal Impact Statement A
OLCC must develop objective criteria for packaging likely to cause minor possession and monitor marketing claims to ensure compliance with anti-child-appeal standards.
Basis: Stakeholder claim · Source: Amendment -1 — proposed amendment
Minors and public health stakeholders
A child finds a discarded edible package but cannot open the child-resistant, individually wrapped container due to strict objective criteria, preventing a fatal overdose.
Basis: Stakeholder claim · Source: Amendment -1 — proposed amendment
Medical marijuana patients with high tolerance
A patient requires precise dosing above 10 milligrams per unit for symptom management; the retail cap forces them to purchase multiple units or seek unregulated sources, increasing cost and potential exposure to contaminants.
Basis: Stakeholder claim · Source: Amendment -1 — proposed amendment
The text legally permits differentiated standards and objective criteria development. However, without precise definitions, enforcement discretion may expand into content-based restrictions not authorized by the statute.
Sources · Amendment -1 — proposed amendment
Standardizing edible potency and packaging reduces accidental pediatric exposure and overconsumption but limits consumer dosing flexibility and imposes compliance costs on manufacturers.
Clearer safety standards and reduced youth access through mandatory child-resistant and individually wrapped formats.
Basis: Stakeholder claim · Source: Amendment -1 — proposed amendment
Predictable retail products that align with public health objectives and minimize misleading marketing.
Basis: Stakeholder claim · Source: Amendment -1 — proposed amendment
Potential mismatch for medical patients needing higher per-unit doses, forcing multi-unit purchases or unregulated alternatives.
Basis: Stakeholder claim · Source: Amendment -1 — proposed amendment
Administrative burden for producers and risk of subjective marketing restrictions if objective criteria are poorly defined.
Basis: Stakeholder claim · Source: Amendment -1 — proposed amendment
high confidence. The amendment text explicitly mandates packaging formats, potency caps, and marketing restrictions. Fiscal impact statements confirm minimal revenue effects. However, rulemaking details and industry adaptation costs remain unquantified.
30 records currently loaded
Records available in the current snapshot.
Earliest loaded signal
Introduced bill text posted
Posted Jan 28, 2026, 3:25 PM PST
Follow the official text for SB 1548 and every amendment branch. Connections come from each amendment's stated base. Horizontal position shows when each document was first posted, when available.
Click a card to isolate its connected lines; use View summary to jump to its details. Horizontal position shows first posting time in Pacific Time. Drag or use the arrow keys to pan. Pinch with two fingers on mobile, or zoom with the controls, +/− keys, or Control/Command + scroll; press 0 to reset. Dashed branches remained proposals.
Selected document summary
Substantial replacement
What the document says to change
Delete lines 5 through 22 and delete pages 2 through 8 and insert:
Oregon records no individual sponsors.
Presession filing record
Printed pursuant to Senate Interim Rule 213.28 by order of the President of the Senate in conformance with presession filing rules, indicating neither advocacy nor opposition on the part of the President.
LC 289 became SB 1548
Mapping document posted: January 5, 2026 at 4:10 PM PST
Informational Meeting — <b>Overview of Behavioral Health Talent Council and LC 216</b> KC LeDell, Senior Behavioral Health Advisor, Office of Governor Tina Kotek Julie Ibrahim, CEO, New Narrative; Behavioral Health Talent Council Vice Chair Eli Kinsley, Director of Operations, Bridgeway Community Health; Behavioral Health Talent Council Vice Chair Rick Treleaven, CEO, BestCare Treatment Services in Central Oregon; Behavioral Health Talent Council Member
Senate Interim Committee on Early Childhood and Behavioral Health introduction work session
Committee meeting: January 14, 2026 at 2:30 PM PST
HR B
Committee introduction motion
Committee meeting: January 14, 2026 at 2:30 PM PST
A motion was made to adopt the listed legislative concepts as committee bills.
Official vote: 5-0-0
Committee introduction allows consideration; it does not imply every member supported the introduced or final text.
Senate carrier
Senator Lisa Reynolds
Third Reading Of Senate Measures · Version A
A carrier presents the measure or report but is not necessarily its sponsor or author.
Records already listed in Activity are not repeated here.
Yex Labs LLC should monitor this measure because the supplied artifact supports small-business incentives, grants, and tax policy and a credible operational, financial, or compliance effect.
78% confidence · deterministic fallback
30 events
Full timeline
30 entries shown.
In committee upon adjournment.
Public Hearing held.
Public Hearing
Heard · Agenda item 3 · Room HR F · Requires cannabinoid edibles to be individually packaged and allows up to 10 milligrams of adult use cannabinoid per individual cannabinoid edible.
IS_Impact SB 1548 A2
Revenue Impact Statement
Amendment -A2 proposed
Public Hearing held.
Public Hearing
Heard · Agenda item 2 · Room HR F · Requires cannabinoid edibles to be individually packaged and allows up to 10 milligrams of adult use cannabinoid per individual cannabinoid edible.
Amendment -A2 proposed
Referred to Economic Development, Small Business, and Trade.
First reading. Referred to Speaker's desk.
Third reading. Carried by Reynolds. Passed.
Ayes, 22; Nays, 5--Broadman, Manning Jr, Meek, Prozanski, Smith DB; Excused, 3--Drazan, Frederick, Linthicum.
Carried over to 02-19 by virtue of adjournment.
Second reading.
Senate Amendments to Introduced bill text posted
Recommendation: Do pass with amendments. (Printed A-Eng.)
Work Session held.
Work Session
Heard and Reported Out with Amendments · Agenda item 3 · Room HR E · Requires cannabinoid edibles to be individually packaged and allows up to 10 milligrams of adult use cannabinoid per individual cannabinoid edible.
Amendment -1 adopted
IS_Impact SB 1548 1
Revenue Impact Statement
Public Hearing held.
Public Hearing
Heard · Agenda item 3 · Room HR E · Requires cannabinoid edibles to be individually packaged and allows up to 10 milligrams of adult use cannabinoid per individual cannabinoid edible.
IS_Impact SB 1548 1
Revenue Impact Statement
Amendment -1 proposed
Referred to Early Childhood and Behavioral Health.
Introduction and first reading. Referred to President's desk.
“Requires cannabinoid edibles to be individually packaged and allows up to 10 milligrams of adult use cannabinoid per individual cannabinoid edible.”
Confirm with the official record.
Supplemental, source-linked analysis from project researchers and community contributors. It is separate from Oregon's official record.